Response to comments on the Scientific Opinion of the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) on the scientific substantiation of a health claim related to “high fibre sourdough rye bread” and reduction of post‐prandial glycaemic responses pursuant to Article 13(5) of Regulation (EC) No 1924/2006

Abstract

EFSA Supporting PublicationsVolume 12, Issue 4 796E Technical reportOpen Access Response to comments on the Scientific Opinion of the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) on the scientific substantiation of a health claim related to “high fibre sourdough rye bread” and reduction of post-prandial glycaemic responses pursuant to Article 13(5) of Regulation (EC) No 1924/2006 European Food Safety Authority (EFSA), European Food Safety Authority (EFSA)Search for more papers by this author European Food Safety Authority (EFSA), European Food Safety Authority (EFSA)Search for more papers by this author First published: 17 April 2015 https://doi.org/10.2903/sp.efsa.2015.EN-796 Published date: 17 April 2015 Question number: EFSA-Q-2015-00014 AboutPDF ToolsExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat References Atkinson FS, Foster-Powell K and Brand-Miller JC, 2008. International tables of glycemic index and glycemic load values: 2008. Diabetes Care, 31, 2281– 2283. EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2011a. General guidance for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal 2011; 9(4):2135, 24 pp. doi:10.2903/j.efsa.2011.2135 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2011b. Scientific Opinion on the substantiation of health claims related to arabinoxylan produced from wheat endosperm and reduction of post-prandial glycaemic responses (ID 830) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011; 9(6):2205, 15 pp. doi:10.2903/j.efsa.2011.2205 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2011c. Scientific Opinion on the substantiation of health claims related to beta-glucans from oats and barley and maintenance of normal blood LDL-cholesterol concentrations (ID 1236, 1299), increase in satiety leading to a reduction in energy intake (ID 851, 852), reduction of post-prandial glycaemic responses (ID 821, 824), and “digestive function” (ID 850) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011; 9(6):2207, 21 pp. doi:10.2903/j.efsa.2011.2207 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2012a. Guidance on the scientific requirements for health claims related to appetite ratings, weight management, and blood glucose concentrations. EFSA Journal 2012; 10(3):2604, 11 pp. doi:10.2903/j.efsa.2012.2604 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2012b. Scientific Opinion on the substantiation of health claims related to alpha-cyclodextrin and reduction of post-prandial glycaemic responses (ID 2926, further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2012; 10(6):2713, 17 pp. doi:10.2903/j.efsa.2012.2713 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2014. Scientific Opinion on the substantiation of a health claim related to high-fibre sourdough rye bread and reduction of post-prandial glycaemic responses pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA Journal 2014; 12(10):3837, 11 pp. doi:10.2903/j.efsa.2014.3837 Volume12, Issue4April 2015796E ReferencesRelatedInformation